Journal article
A novel way to quantify schizophrenia symptoms in clinical trials
Oleg N Medvedev, Michael Berk, Olivia M Dean, Ellie Brown, Margaret H Sandham, Joanna F Dipnall, Robert K McNamara, Alexander Sumich, Christian U Krageloh, Ajit Narayanan, Richard J Siegert
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION | WILEY | Published : 2020
DOI: 10.1111/eci.13398
Abstract
BACKGROUND: A major problem in quantifying symptoms of schizophrenia is establishing a reliable distinction between enduring and dynamic aspects of psychopathology. This is critical for accurate diagnosis, monitoring and evaluating treatment effects in both clinical practice and trials. MATERIALS AND METHODS: We applied Generalizability Theory, a robust novel method to distinguish between dynamic and stable aspects of schizophrenia symptoms in the widely used Positive and Negative Symptom Scale (PANSS) using a longitudinal measurement design. The sample included 107 patients with chronic schizophrenia assessed using the PANSS at five time points over a 24-week period during a multi-site clin..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by Royal Society of New Zealand Catalyst
Funding Acknowledgements
The authors declare no conflicts of interest in regards of this paper. MB is supported by a National Health and Medical Research Council (NHMRC) Senior Principal Research Fellowship (1059660 and 1156072). This article resulted from a meeting of the authors in April 2017 funded by a Royal Society of New Zealand Catalyst (Seeding General) Grant awarded to RS in 2016 16-AUT-024-CSG.